SecBot SecBot

QURE drug pipeline

uniQure N.V. · 3 rated drugs
$21.88
−8.1% 1-day · Nov 16
Next catalyst
May 1, 2027
ifezuntirgene inilparvovec PDUFA date · in 166 days
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
3
1 bullish · 1 bearish · 1 neutral
Phase 3 trials
0
0 with results posted

Upcoming catalysts

1 dated
  1. May 1, 2027166d
    ifezuntirgene inilparvovec
    PDUFA date · Huntington's disease

Drugs

soonest catalyst first
▲ bullish
Impact
PhasePhase 1/2 (pivotal for accelerated approval)
Time to marketBLA submission planned for Q3 2026; FDA accelerated approval decision likely 6-10 months after submission (potentially H1 2027)

AMT-130 AAV5-miHTT Updated Jul 2

What to watch

The BLA submission in Q3 2026 is the key near-term catalyst. The FDA has already aligned on the submission package, but final acceptance and review timelines remain to be seen. Watch for the official BLA filing announcement, PDUFA date assignment, and any FDA Advisory Committee meeting. The $225M June 2026 offering funds commercialization readiness but added ~8% dilution. Analysts are bullish (16 buy vs 5 hold, mean PT ~$64.59, ~47% upside from ~$44).

Bull case
  • First disease-modifying therapy for Huntington's disease, massive unmet need with no approved treatments that slow progression
  • High-dose showed 75% slowing of disease progression on cUHDRS at 36 months (p=0.003) and 60% on TFC (p=0.033), highly statistically significant for a Phase 1/2
  • FDA granted RMAT (first-ever for HD), Breakthrough Therapy, and Fast Track designations, multiple accelerated pathways
Bear case
  • Pivotal data comes from a relatively small Phase 1/2 trial (n=26 US + European cohort) vs external controls, not a randomized double-blind sham-controlled trial, weaker evidence standard
  • Safety concerns around invasive neurosurgical delivery, requires MRI-guided infusion directly into the brain, which limits patient accessibility and carries procedural risks
  • Durability beyond 3 years is unknown; gene therapy is permanent and cannot be removed if long-term safety issues emerge
● neutral
Impact
PhaseApproved (FDA approval November 22, 2022); pivotal Phase 3 HOPE-B trial completed primary analysis, long-term follow-up
Time to marketApproved and on the market since November 2022 (U.S.), commercialized worldwide by CSL Behring — but currently constrained by a temporary global stockout announced March 2026

HEMGENIX etranacogene dezaparvovec Updated Aug 1

What to watch

For QURE holders, stop thinking of HEMGENIX as the thesis: the stock now trades on AMT-130 (Huntington's), BLA submission on track for Q3 2026 and topline 4-year data expected September 2026. Watch HEMGENIX only as a modest cash-flow line: CSL has been in a manufacturing-related temporary global stockout since March 2026 and, as of its July 24, 2026 update, supply was still being actively managed, any resumption announcement or CSL sales disclosure is a minor, non-binary event for QURE (which already sold $375M of its royalty tier to HealthCare Royalty/Sagard).

Bull case
  • First-ever FDA-approved gene therapy for hemophilia B (Nov 22, 2022), a one-time infusion with durable benefit versus lifelong prophylaxis, supported by HOPE-B data: mean factor IX activity of 39% at six months and 36.7% at 24 months, with 3-year durability data reported by CSL in December 2023.
  • Commercialized by a large partner (CSL Behring), which licensed global rights in June 2020 for $450M upfront plus up to $1.6B in milestones, uniQure got paid early and de-risked development.
  • uniQure monetized its lowest royalty tier on HEMGENIX net sales for a $375M upfront (deal worth up to ~$400M, capped at 1.85x purchase price through June 30, 2032 or 2.25x through Dec 31, 2038), extending cash runway without new dilution at the time.
Bear case
  • CSL declared a temporary GLOBAL stockout of HEMGENIX on March 17, 2026 (manufacturing-related per FiercePharma), delaying treatment for patients in countries with commercial access; the July 24, 2026 CSL update shows supply was still being actively managed, a commercial overhang with no dated resolution.
  • HEMGENIX is no longer a meaningful value driver for QURE: total company revenue was only $16.1M in 2025 and $5.8M in Q2 2026, while the market cap (~$2.3B per local analysis) and analyst attention are centered on AMT-130 (Huntington's), HEMGENIX-specific news moves QURE little.
  • uniQure already sold its lowest royalty tier ($375M upfront to HealthCare Royalty/Sagard), so a large share of the drug's future upside no longer accrues to QURE shareholders.
▼ bearish
Impact
PhasePhase 1/2 (discontinued)
Time to marketNever — program discontinued in May 2026; no path to approval.

AMT-162 Updated Aug 1

What to watch

AMT-162 is a closed chapter, uniQure (QURE) stopped the program in May 2026 after a dose-limiting toxicity and unfavorable preliminary data, so there is nothing to trade on this drug. QURE stock now trades purely on AMT-130 (Huntington's: UK MAA expected Q3 2026, FDA Type B meeting), AMT-260 and AMT-191, plus a ~10% dilutive June 2026 offering; watch those catalysts, not AMT-162.

Bull case
  • Conceptually attractive: a one-time gene therapy that knocks down SOD1 protein could avoid the lifelong repeat lumbar-puncture dosing of the approved rival QALSODY (tofersen); the first EPISOD1 cohort cleared IDMC review in January 2025 with no significant safety concerns (biospace.com PR).
  • Negligible company-level damage: AMT-162 was a minor pipeline program and its discontinuation doesn't threaten uniQure's ~$586.6M cash position and runway into 2H 2029, so the drug's failure has little lasting impact on QURE's thesis (stocktitan Q1 2026 report).
  • Safety follow-up of the five dosed patients continues, so data from the program may still inform uniQure's AAV delivery platform and future vector designs (adisinsight.springer.com trial note).
Bear case
  • Development is discontinued (announced May 5, 2026): a serious adverse event judged a dose-limiting toxicity plus unfavorable preliminary efficacy/safety data from the five-patient EPISOD1 trial ended the program, so AMT-162 has no future commercial value (precisionmedicineonline.com; uniqure.gcs-web.com Q1 2026 release).
  • Competition was already entrenched: Biogen/Ionis' QALSODY (tofersen) won FDA accelerated approval for SOD1-ALS in April 2023 (first approved therapy targeting a genetic cause of ALS) and EU approval, setting a high bar for a Phase 1/2 gene therapy (investors.biogen.com).
  • Tiny, safety-hobbled dataset: only five patients were ever dosed, and the dose-limiting toxicity highlights real safety risk of high-dose intrathecal AAV delivery; the pipeline page itself confirms enrollment was paused after the SAE (uniqure.com).

Other drugs in filings and trials

no drug report yet
  • ifezuntirgene inilparvovec Next: PDUFA date · May 1, 2027